Would weak PR positivity make you consider adjuvant endocrine therapy for a young pre-menopausal woman with a HER2 positive, ER negative breast cancer?

I would discuss the uncertainties, and would offer tamoxifen at the most (I would not subject the patient to the toxicities of OFS and AI). I would also have a low threshold to discontinue tamoxifen if there are toxicities. If there are minimal to no side effects, it may be worthwhile getting the th...